

ENMC MENTORS

Prof. Annemieke Aartsma-Rus | Leiden, The Netherlands



PROF. ANNEMIEKE AARTSMA-RUS is a Professor of Translational Genetics at the Department of Human Genetics of the Leiden University Medical Center.

She played an important role in the development of the antisense mediated exon skipping therapy for Duchenne muscular dystrophy during her PhD research

(2000-2004) at the Leiden University Medical Center (the Netherlands).

As of December 2007 she became leader of the "DMD exon skipgroup". Since 2013, she has a visiting professorship at the Institute of Genetic Medicine of Newcastle University (UK). She is President of the Oligonucleotide Therapeutics Society (2019-2021), vice-chair of COST Action "Delivery of antisense RNA therapies" and member of the Core Committee of the TREAT-NMD Advisory board for Therapeutics (TACT). Recently she chaired

the TREAT-NMD Executive Committee. Thus far, she has published over 200 peer-reviewed papers and 11 book chapters, as well as 15 patents and has edited one book. She has given many invited lectures at meetings, symposia and workshops as well as patient/parent organizations meetings, where she is known for her ability to present science in a clear and understandable way. Annemieke has successfully applied for numerous grant applications and serves on many editorial and advisory boards.

Drs Anita Atema | Nijmegen, The Netherlands



DRS ANITA ATEMA is an experienced and results-driven executive director and general manager with strong personal commitment to patient engagement and access. She has

broad experience in various (bio/orphan) pharmaceutical companies in e.g. marketing, sales, medical affairs, market access, corporate

affairs and patient advocacy.

Anita Atema worked for more than 25 years for various pharmaceutical companies such as Sandoz (now Novartis), Amgen, Roche and Celgene both at the local and the international level. She recently joined Jazz Pharmaceuticals, Nijmegen, The Netherlands, as the national country manager. Anita specialized in the following areas: Hematology, Oncology, Inflammation & Immunology, Targeted Cancer Therapy (CAR-T) and Epigenetics. In the different positions she held, Anita was

responsible for the successful launches of 5 (orphan) drugs in the Dutch market in more than 10 diseases by creating unique patient access solutions. Her additional international experience is the implementation of patient engagement in all phases of the day to day business (from clinical trials to market access to (launch) campaigns).

Dr Alan Beggs | Boston, USA




DR ALAN H. BEGGS PhD is the Director of the Manton Center for Orphan Disease Research at Boston Children's Hospital and Sir Edwin & Lady Manton Professor of Pediatrics at Harvard

Medical School. Following undergraduate studies at Cornell University, Dr Beggs obtained his PhD in Human Genetics at Johns

Hopkins University, with subsequent post-doctoral fellowship training in medical and molecular genetics at Johns Hopkins and Boston Children's hospitals. He has general expertise in laboratory and clinical applications of genetics to human disease, and since 1992 has directed an independent research program in the Division of Genetics and Genomics. Over the years, he has used the toolset of human molecular genetics to study normal biology and pathophysiology of a variety of disorders including muscular dystrophies,

cardiac arrhythmias, developmental brainstem defects, hereditary anemias, sudden infant death syndrome, and congenital myopathies. Dr Beggs has been a standing and ad hoc member of numerous NIH study sections and grant reviewer for the Muscular Dystrophy Association and March of Dimes. He is a member of several scientific advisory boards and boards of directors for nonprofit and commercial entities.

Prof. Olivier Benveniste | Paris, France



PROF. OLIVIER BENVENISTE has the great opportunity to control all the steps of the translational medicine process, from the immediate identification of myositis patients

during their clinics or their hospitalization in his national reference centre for myositis, the in depth characterization of the patient'

phenotype in a standardized database, their sampling and bio banking (muscle, PBMC, sera), fundamental researches (in his lab at Sorbonne University) from this biobank (in depth immunoprofiling of PBMC by CyTOF analyses, effect on muscle of myositis specific auto-antibodies, effect on muscle of type 1 interferons, research of new biomarker), the definition of the best outcome measures for clinical trials, the physiopathological "bench to the bedside" studies, the development of clinical academic and/or industrial clinical

trials, as for example, the RAPAMI trial testing rapamycin (sirolimus) against placebo in inclusion body myositis.

ENMC MENTORS

Dr Carsten Bönnemann | Bethesda, USA



DR CARSTEN BÖNNEMANN received his MD from Freiburg University, Germany. He completed pediatric training in Germany. A residency in pediatric neurology at

Harvard was followed by postdoctoral work with Dr Louis Kunkel at Children's Hospital Boston working on the molecular genetics of

muscular dystrophy. In 2002 he joined the Children's Hospital of Philadelphia/University of Pennsylvania as Assistant Professor, and became Co-Director of the Neuromuscular Programme and Director of the Neurogenetics Clinic. He joined the National Institute of Neurological Disorders and Stroke (NINDS/NIH) in 2010 as Senior Investigator and Chief of the Neuromuscular and Neurogenetic Disorders of Childhood Section.

Dr Bönnemann was a Pew Fellow in the Biomedical Sciences. He received the 2009

Derek Denny Brown Neurological Scholar Award. Research in Dr Bönnemann's laboratory revolves around molecular mechanisms underlying early onset muscle disease (congenital muscular dystrophies, congenital myopathies, and reducing body myopathy). Dr Bönnemann is involved in many neuromuscular networks, such as the WMS, TREAT-NMD, ENMC and has an impressive track record of scientific publications, lectures and editorial work making progress in the research of neuromuscular patients.

Dr James Dowling | Toronto, Canada



DR JAMES DOWLING is a clinician-scientist focused on gene discovery and therapy development for childhood muscle diseases. Dr Dowling received his B.Sc. and M.Sc. from Yale

University and his MD/PhD from the University

of Chicago. He did his residency in child neurology at Children's Hospital of Philadelphia and completed postdoctoral research at the University of Pennsylvania and Michigan. Before coming to Toronto, he was an assistant professor at the University of Michigan from 2009-2013.

Jim Dowling's clinical expertise is in childhood neuromuscular disorders and he is considered one of the leading authorities on the diagnosis

and management of congenital myopathies. His research examines questions of disease pathogenesis and therapy development for congenital myopathies and childhood muscular dystrophies. He has authored or co-authored more than 100 peer reviewed manuscripts and been fortunate to enjoy funding from several sources, including CIHR, NIH, MDA, and Genome Canada.

Prof. Bertrand Fontaine | Paris, France



PROF. BERTRAND FONTAINE is a medical researcher and neuromyologist at the Salpêtrière Hospital in Paris and a Professor of Medicine at the Sorbonne University. Since

October 2019, Bertrand is Medical and Scientific Director of the Institute of Myology, Paris, France.

Prof. Fontaine is one of the discoverers of the role of ion channels, molecules that transmit electrical signals, in neuromuscular diseases. Between 2003 and 2008 he was the Director of the Sorbonne-Université and the INSERM (U546) Research Institute. Since September 2018, he has been Director of the Myology Research Center (UMR 974) and was appointed on July 11, 2019 as head of the Neuro-Myology Department, Institute of Myology.

Prof. Fontaine has received many awards for his outstanding medical research work and for his managerial activities. He is an appointed member of both national (France) and international Executive, Editorial and Scientific boards (e.g. International Committee of the American Academy of Neurology, National Institute of Health-USA) and is often asked for communications (interviews and publications) to the general public.

Sarah Foye | Pine Brook, NJ, USA



SARAH FOYE, BS, is an occupational therapist and mother to an adult son with congenital titinopathy. She is an advocate for families with titin related muscle and heart disorders and is

the founder of Team Titin, Inc. Team Titin is a nonprofit with the mission to serve those living with, caring for or researching titin (TTN) related muscle and heart disorders. See titinmyopathy.com to learn more. She is also part of the Advisory Team for the Congenital

Muscle Disease International Registry (CMDIR.org). She served on the 2022, 2021 and 2019 SciFam planning team. She was the patient representative in the 219th ENMC International Workshop on Titinopathies. She has acted as a project lead and outreach coordinator for two Patient Centered Outcomes Research Institute (PCORI) engagement awards for A Foundation Building Strength for Nemaline Myopathy (2016-2017 and 2021 to present). She reviewed grants as a Consumer Reviewer for the Department of Defense Peer Reviewed Medical Research Program in 2018 & 2020. Her clinical experience has included work at a world-renowned inpatient rehabilitation

hospital working with adults with disabilities as well as 10 years as a school-based pediatric OT. As a legislative advocate she has participated for many years in the Rare Disease Legislative Advocates program, the MDA advocacy Institute (2022) and is a recent member of EveryLife Foundation Community Congress (2022). She is also a member of Global Genes - Global Advocacy Alliance (GAA) and an RD-Connect Community Member since 2018. Sarah considers her most valuable credentials to be "Mom" and is PASSIONATE about making a global impact for people with neuromuscular disease.

ENMC MENTORS

Prof. Cynthia Gagnon | Montreal, Canada




PROF. CYNTHIA GAGNON is a senior career-award researcher specializing in adult genetic neuromuscular disorders. She holds a professorial appointment at the School of Rehabilitation at the

University of Sherbrooke. She is the scientific director of the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN) and is a researcher at the Centre de recherche Charles-Le Moyne-Saguenay-Lac-St-Jean sur les innovations en santé.

She trained as an occupational therapist at McGill University. She has a doctoral degree in experimental medicine from Laval University and pursued a postdoctoral fellowship in program evaluation at Montreal University. Her work aims at improving clinical care and speeding up trial readiness in the most prevalent neuromuscular diseases in Canada. Her main interest is to document the natural history of the disease through an interdisciplinary perspective to be able to document the progression of the disease and to identify significant predictor and explanatory factors related to participation in daily activities and social roles of patients such as work and autonomous

living. Her other interest is to define the best outcome measures to assess potential therapeutic targets such as muscle strength, fatigue or cognitive functions. She also works on developing knowledge translation strategies related to rare diseases to ensure effective and just-in-time knowledge translation to the interdisciplinary team through different strategies including wiki, articles, clinical practice guidelines to improve clinical care for patients and their families. She is involved in several international projects in relation to myotonic dystrophy type 1 (DM1), oculopharyngeal muscular dystrophy (OPMD) and autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).

Prof. Heinz Jungbluth | London, United Kingdom



PROF. HEINZ JUNGBLUTH is Professor of Paediatric Neurology at King's College London and Consultant Paediatric Neurologist at the Evelina Children's Hospital, Guy's &

St Thomas' NHS Foundation Trust, London, UK, with more than 25 years clinical experience in Paediatric Neurology.

His main research interest is in early-onset neuromuscular and neurodevelopmental disorders. He has been particularly interested in the clinical and genetic characterization of the congenital myopathies, in particular those affecting excitation-contraction coupling due to mutations in the skeletal muscle ryanodine receptor (RYR1) gene, and related episodic disorders such as malignant hyperthermia (MH) and (exertional) rhabdomyolysis (ERM). Other neuromuscular interests include congenital myasthenic syndrome, juvenile myasthenia gravis as well as muscle magnetic

resonance imaging. He and his team have also introduced the concept of congenital disorders of autophagy, a novel class of inborn neuromuscular and neurometabolic conditions linking aberrant neurodevelopment with common adult-onset neurodegenerative disorders such as dementia, Parkinson's disease and ALS.

He has published widely and is a member of national and international expert consortia concerned with improving the care and developing therapies for early-onset neuromuscular and neurological disease.

Prof. Eric P. Hoffman | New York, USA




PROF. ERIC P. HOFFMAN is Professor of Pharmaceutical Sciences and Associate Dean for Research, Binghamton University – SUNY, and has co-founded and holds management positions

in three academic spin-off companies focused on neuromuscular disease (CEO of ReveraGen

BioPharma; Vice President of AGADA BioSciences; board member of TRiNDS LLC). Prof. Hoffman received his PhD in Drosophila molecular genetics from Johns Hopkins University and transitioned to human molecular genetics as post-doctoral fellow with Louis Kunkel at Boston Children's Hospital and Harvard Medical School working on the identification of the Duchenne muscular dystrophy gene and dystrophin protein. He has held faculty positions at Harvard

Medical School (1988-1990), University of Pittsburgh (1990-1998), George Washington University and Children's National Medical Center (1998-2016). He co-founded the Cooperative International Neuromuscular Research Group (CINRG) and has helped lead drug development programs of viltolarsen (exon skipping), and vamorolone. He is an inventor on over 20 patents and has authored over 500 publications.

Prof. Hanns Lochmüller | Ottawa, Canada



PROF. HANNS LOCHMÜLLER is a Professor of Neurology at the University of Ottawa Faculty of Medicine and The Ottawa Hospital Department of Medicine. He is a

neurologist and clinical academic specializing in genetic neuromuscular disorders and rare disease. Hanns is Senior Scientist at the

Children's Hospital of Eastern Ontario (CHEO) Research Institute. Hanns trained as a neurologist in Munich, Germany and in Montreal, Canada. From 2007 to 2017, he held the chair of experimental myology at the Institute of Genetic Medicine at Newcastle University in the UK. He continues to hold a scientific appointment at the Department of Neuro-pediatrics and Muscle Disorders of the Medical Center – University of Freiburg in Germany and as visiting scientist at the Centro Nacional de Análisis Genómico (CNAG), Centre for

Genomic Regulation, Barcelona in Spain. In addition to his scientific and clinical research interests, he is internationally active in rare disease science policy and research collaborations. He chaired the IRDIRC and TREAT-NMD. He initiated and coordinated the highly successful "RD-Connect" international infrastructure for rare disease data and biosample sharing and analysis, MD-net and EuroBio-Bank, a European (and Canadian) network of biobanks for rare disorders.

ENMC MENTORS

Prof. Annamaria De Luca | Bari, Italy



PROF. ANNAMARIA DE LUCA is Full Professor of Pharmacology specialized in pre-clinical in vivo and ex vivo studies of inherited and acquired neuromuscular disorders. In this general frame, she

has a long lasting experience in preclinical research on pharmacological treatments for DMD and muscle channelopathies and collaborates with leading scientists in the field. She developed multidisciplinary assays for mdx

mice and largely contributed to standardization of methods used to test pathology progression and drug efficacy, especially muscle functionality and electrophysiology. Annamaria has a profound knowledge of mouse physiology and pathology as well as of pharmacodynamics and pharmacokinetic topics for classical and innovative approaches, and hence of the critical points that make out the quality of a study in translational research of novel therapeutics. The results of her research led to registration of novel and repurposed drugs as orphan drugs, for various muscle disorders. Annamaria De Luca is

actively engaged in the pre-clinical work within TREAT-NMD and started working at the harmonization of preclinical studies on mdx before TREAT-NMD was launched. Since 2008, she has been involved in the TREAT-NMD Advisory Committee of Therapeutics (TACT), first as pharmacologist and pre-clinical expert, since 2015 as member of the Core committee. Annamaria is Chair of TACT from November 2018 for the three years round and voted member of the Executive Committee of TREAT-NMD since 2020.

Dr Andrew Mammen | Bethesda, USA



DR ANDREW MAMMEN is currently Associate Director of the Johns Hopkins Myositis Center and Investigator of the National Institutes of Health (NIH) in Bethesda, USA.

After obtaining his MD and PhD at Johns Hopkins, Dr Mammen completed his

neurology residency and neuromuscular fellowship at the same institution. He co-founded the Johns Hopkins Myositis Center in 2007, where he and his colleagues discovered a novel form of autoimmune myopathy associated with statin use and autoantibodies recognizing HMG-CoA reductase, the pharmacologic target of statins. In 2014, Dr Mammen moved to the NIH, where he is an Investigator and Leader of the Muscle Disease Unit. His laboratory

focuses on understanding the pathological mechanisms underlying disease in dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and inclusion body myositis. In addition to seeing myositis patients at the NIH Clinical Center, he maintains an appointment as Adjunct Professor of Neurology and Medicine at Hopkins, where he continues to see patients at the Myositis Center.

Dr Thomas Meier | Basel, Switzerland



DR THOMAS MEIER is a dynamic life-science entrepreneur who established Santhera Pharmaceuticals as successful Biotech/Specialty Pharma company in Switzerland. In the

past 20 years he held executive manager positions (CSO and CEO) at Santhera and

successfully executed merger/acquisitions, product licensing and turn-around situations. He also is co-founder of SEAL Therapeutics, developing an innovative gene therapy approach for LAMA2-related muscular dystrophy.

In 2020 Dr Meier became Managing Partner at Viopas Venture Consulting. Currently Thomas holds Board positions and advises several private and public pharma/biotech companies. Dr. Meier has a PhD in Biology and is lecturer

in neurosciences at the Biozentrum, University of Basel. He is an internationally recognized scientist with track record in clinical research of neuromuscular and other orphan diseases.

Prof. Anders Oldfors | Gothenburg, Sweden



PROF. ANDERS OLDFORS studied medicine in Gothenburg, Sweden. After his PhD thesis on the perineurium in 1980 he did a postdoc with Michel Fardeau in Paris, 1981, learning muscle histopathology. During specialization in surgical and neuropathology, he initiated diagnostic service and research in muscle

pathology in Gothenburg. The research was initially focused on mitochondrial diseases in an interdisciplinary network of pioneers. He started early to combine pathology and genetics in the lab to identify new diseases, mainly in the field of congenital myopathies such as myosin myopathies and glycogen storage diseases. Another longstanding and still ongoing project concerns inflammatory myopathies especially inclusion body myositis. After organizing the 9th World Muscle Society (WMS) international congress in Gothenburg

2004, he has been a continuous member of the Executive Board of WMS and a member of the Editorial Board of Neuromuscular Disorders, the official journal of WMS. He also served for a period in the ENMC scientific committee and several other scientific priority committees. At present Anders Oldfors is Senior Professor at the University of Gothenburg and Consultant Pathologist at the Sahlgrenska University Hospital.

ENMC MENTORS

Prof. Maria Pennuto | Padova, Italy



PROF. MARIA PENNUTO is a Professor of Molecular Biology at the Department of Biomedical Sciences of the University of Padova and a Group Leader at the Veneto Institute of

Molecular Biology (VIMM). After graduating from the University of Rome "La Sapienza", she obtained her Ph.D. in Cellular and Molecu-

lar Biology at the University of Milan, Italy, followed by post-doctoral training on neurological diseases at San Raffaele Scientific Institute, and at the NINDS, NIH in the USA, and Staff Scientist position at the Neurology Department of the University of Pennsylvania. In 2009 she returned to Italy to direct a research group working on the pathogenesis of motor neuron and neuromuscular diseases. Prof Pennuto identified several drugs with therapeutic potential that led to two phase II clinical trials. She authored more than 80

peer-reviewed papers, and her research is supported by National and International grant agencies. Prof Pennuto mentored several students (BS, MS, and PhD) and post-doctoral fellows, five of which obtained a position as independent investigators in academia or the industry in Italy and abroad.

Prof. Markus Rüegg | Basel, Switzerland



PROF. MARCUS RÜEGG is Professor for Neurobiology at the Biozentrum, University of Basel, Switzerland. He studied Biochemistry and Neurobiology in Zurich and Stanford and was co-founder

and member of the management of MyoContract, now called Santhera Pharmaceuticals, a biotech company that dedicated to develop therapies for neuromuscular diseases. Prof. Rüegg is an internationally recognized expert in neuromuscular research and has published numerous scientific papers in the field of neuromuscular research. In recent years, his work has also been devoted to the

study of therapeutic interventions in mouse models for congenital muscular dystrophy. Prof. Rüegg is also partner of the network TREAT-NMD and he has been an active member of the ENMC Research Committee for six years.

Prof. Ulrike Schara-Schmidt | Essen, Germany



PROF. ULRIKE SCHARA-SCHMIDT is Professor for Neuropaediatrics and Neuromuscular Diseases and is one of the leading national and international experts in these areas

of clinical care and research. She heads the Department of Neuropaediatrics and the Centre for Neuromuscular Diseases in Children and Adolescents at the Children's Hospital of the University Hospital Essen. She is president of the Society for Neuropaediatrics, vice president of the German Brain Council, chair of the Ethics Committee of the Medical Faculty Duisburg-Essen and member of numerous

national and international committees. She has also been a member of the ENMC Research Committee from 2012-2018. Prof. Schara-Schmidt and her team are involved in international studies.

Prof. Bert Smeets | Maastricht, The Netherlands



PROF. BERT SMEETS is Professor in Clinical Genomics with a focus on Mitochondrial Diseases. He is an internationally distinguished clinical molecular geneticist. He founded the

Genome Center Maastricht and established a Master Programme in Systems Biology at Maastricht University (Maastricht, NL).

Prof. Smeets studied Molecular Biology at the University of Nijmegen, where he did a PhD on myotonic dystrophy.

For 10 years he worked in Nijmegen, and since 1995 at Maastricht University, The Netherlands, where he became Professor in 2010, combining research with genetic testing services.

His research concentrated on the genomics of mitochondrial disorders. His research involves identifying genetic defects by next-generation sequencing, studying the pathophysiology and mtDNA bottleneck mechanism in cell lines, iPSC and zebrafish models, developing new treatment options (compounds or autologous stem cells) and preventing the transmission of mitochondrial diseases, either by prenatal diagnosis, preimplantation genetic diagnosis

or whole exome preconception screening. His research is funded by a broad variety of national and international funding agencies and he published over 225 original research articles, reviews and book chapters (H-Index 49).

ENMC MENTORS

Prof. Volker Straub | Newcastle, UK



PROF. VOLKER STRAUB is the Deputy Dean, Harold Macmillan Professor of Medicine and Professor of Neuromuscular Genetics at the Institute of Translational and Clinical

Research at Newcastle University, United Kingdom. He is the Director of the university's John Walton Muscular Dystrophy Research Centre and holds honorary clinical appointments with the Newcastle upon Tyne Hospitals

NHS Foundation Trust and the North Tees and Hartlepool NHS Foundation Trust.

He was trained as a paediatric neurologist at the University of Düsseldorf and the University of Essen in Germany. He wrote his PhD thesis on Duchenne muscular dystrophy (DMD) and worked as a postdoctoral research fellow in Dr Kevin Campbell's laboratory at the Howard Hughes Medical Institute at the University of Iowa in Iowa City, Iowa, USA, on limb girdle muscular dystrophies (LGMD).

He was the co-founder of the EU FP6 funded network of excellence for genetic neuromuscular diseases, TREAT-NMD, which he

coordinated together with Kate Bushby.

He is PI for a number of natural history and interventional trials in DMD, LGMD, Pompe disease, spinal muscular atrophy and other NMDs. He recently chaired the European MYO-MRI COST Action to develop applications of MR imaging and spectroscopy techniques in neuromuscular disease. He is part of the steering committee of the MRC Centre for neuromuscular diseases and is now President of the World Muscle Society. He is author on > 300 peer-reviewed publications.

Prof. Vincent Timmerman | Antwerp, Belgium



PROF. VINCENT TIMMERMAN is full professor at the University of Antwerp (UA). His Peripheral Neuropathy Research Group started in 1996 with mapping and identifying genes

associated with inherited peripheral neuropathies. They study the effect of mutations on the normal functioning of genes in neuronal

and non-neuronal cell lines, including neurons differentiated from human induced pluripotent stem cells (iPSC). They gained knowledge with diverse gene cloning technologies and have phenotyped -in house made- mouse and Drosophila models for peripheral neuropathies. So far, Prof. Timmerman supervised 10 postdocs and 15 PhD students (6 on-going PhDs). He is a lecturer and supervisor of bachelor/master students at the UA. Further, he became a partner in the UA Research Excellence Center (OEC µNeuro) on: 'Multidi-

mensional analysis of the nervous system in health and disease'. He was also an active partner in the FP7 Neuromics, H2020 Solve-RD project, SAB member of the MRC Center for Neuromuscular Diseases and member of the Inherited Neuropathy Consortium - Rare Disease Clinical Research Consortium (USA). Further, he was the secretary of the CMT and related disease consortium (CMTR) within the Peripheral Nerve Society, and currently member of the PNS program committee. He is a reviewer for several granting organizations in Europe.

Dr Selma Tromp | Leiden, The Netherlands



DR SELMA TROMP is Neurologist / Clinical Neurophysiologist at the Leiden University Medical Center, The Netherlands. She worked since 2008 at St. Antonius Hospital, Nieuwegein, the

Netherlands, where she was responsible for


the education of residents and medical management of the department.

After her PhD, Dr Tromp started her career as Neurologist / Clinical Neurophysiologist at the departments of Clinical Neurophysiology and Neurology of the Academic Hospital Maastricht, the Netherlands. Dr Tromp has held several board functions.

From 2013, Dr Tromp was member / chair of the educational committee of the Dutch

Society for Clinical Neurophysiology; from 2009-2017, she was member of the board of the Dutch Society for Neurology and in the last three years she was the Chair of this board. From Nov 2017-2020, Dr Tromp was member of the Supervisory Board of the Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands. Currently, she is member of the board of the Dutch Federation of Medical Specialists, with her special focus on quality of care.

Prof. Bjarne Udd | Helsinki, Finland



PROF. BJARNE UDD, born in Finland, received his MD from the University of Berne, Switzerland in 1975, and completed Residency training in Neurology at the University Hospital in


Umeå, Sweden, and the University Hospital in Helsinki, Finland. He received his PhD degree from Helsinki University in 1992 with the thesis

on a new type of muscular dystrophy, causing the distal Tibial muscular dystrophy (TMD) in heterozygotes and severe LGMD R10 in homozygote patients. With academic positions (docent) at Tampere University from 1997 he was appointed Professor of Neurology in Neuromuscular Disorders in 2007 and the Head of the Neuromuscular Research Center, Tampere University Hospital. He is currently PI of the neuromuscular research group in Helsinki, at the Folkhälsan Research Center. Prof. Udd is member of many international

research boards in Neuromuscular diseases. His research focuses on very rare neuromuscular diseases: clinical and molecular genetic research on muscular dystrophies, in particular: distal myopathies, rimmed vacuolar myopathies, limb-girdle dystrophies and myotonic dystrophy type 2. Since the first ever description of human titinopathy the research efforts have resulted in more than 25 primary descriptions of new muscle diseases many with previously unknown myopathy genes.

ENMC MENTORS

Prof. J. Andoni Urtizberea | Paris, France



PROF. J. ANDONI URTIZBEREA is a physician trained in Paris University and certified both in paediatrics and physical medicine and rehabilitation. After graduating in parallel

from the Institut d' Etudes Politiques de Paris in 1987, he served many years as Medical Director of the AFM-Telethon and then as

General Delegate of the Institut de Myologie of Paris (1993-2000). As Scientific Director of the ENMC (1999-2005) and together with AFM's support, he contributed to the establishment of many worldwide networks in myology, an emerging discipline in the medical field.

He served until December 2019 as a part-time clinical myologist in Hendaye, France (APHP) and as deputy coordinator of the French Neuromuscular Network (FILNEMUS) in Marseilles. Over the past twenty years, he

headed various worldwide educational events dedicated to myology (in France, Russia, Latin America and, more recently in the Middle-East). He is a regular visiting professor in various countries and a consultant for many pharma involved in the field. Ideally located at the intersection of industry, patient advocacy groups and academia, his main objective is to raise more awareness about these rare conditions notably in emerging countries and more specifically in the context of novel cutting-edge therapies.

Prof. Mariz Vainzof | São Paulo, Brazil



PROF. MARIZ VAINZOF is Professor of Genetics, Head of Laboratory at the Human Genome Research Center, University of Sao Paulo (USP), São Paulo, in Brazil. She graduated

in Biology, at the Instituto de Biociências (IB-USP) in 1977, obtained a MSc in genetics in the Department of Biology in 1983 and a

Ph.D. in the Department of Genetics in 1989. She was trained in the Department of genetics, The Hospital for Sick Children, Toronto, Canada. Since more than 30 years, Prof. Mariz Vainzof is Head of the muscle protein and Comparative Histopathology at the Human Genome and Stem Cell Research Center, IB-USP.

Prof. Mariz Vainzof has an extensive list of scientific publications, books and has won many awards for her research activities. She is member of the International Consortium on

Nemaline Myopathy, International Standard of Care Committee for Congenital Myopathies, and several other international and national organizations involved in muscle research. Last but not least, Mariz is highly involved with the Muscle World Society, being at the moment part of the International Congresses program committee.

Prof. Kathryn Wagner | Basel, Switzerland



PROF. KATHRYN WAGNER received her MD and PhD in molecular neuroscience from the Johns Hopkins School of Medicine. Following residency training in neurology and clinical

fellowships in neuromuscular and neuro-genetic disorders, Kathryn was a postdoctoral fellow in molecular biology where she

described the loss of myostatin in the mdx model of DBMD and in an otherwise healthy human infant. She continued this work, elucidating the role of myostatin and related signaling molecules in muscle regeneration in her own laboratory at Hopkins and is currently Professor Emeritus of Neurology and Neuroscience at the Johns Hopkins School of Medicine. She was the founding director of the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute where she cared for pediatric and adult individuals with neuro-

muscular disorders and conducted investigator and industry initiated clinical trials. In order to advance drug development for rare disorders, she transitioned to industry where she served as Vice President, Global Head of Neuromuscular Diseases at Roche leading late-stage programs in DMD, SMA, gMG and FSHD and obtaining multiple regulatory approvals. More recently, she joined Novartis as Vice President, Global Head of Translational Medicine, Neuroscience where she directs early development of a broad portfolio.

Dr Carina Wallgren-Pettersson | Helsinki, Finland



DR CARINA WALLGREN-PETTERSSON is a Medical Doctor specialised in Medical Genetics, working as a Principal Investigator at The Folkhälsan Institute of Genetics and Department of

Medical and Clinical Genetics, University of Helsinki, Biomedicum Helsinki. She coordinates the scientific efforts of the Research Group on

Nemaline Myopathy and Related Disorders, together with her Co-PI Katarina Pelin, PhD. Carina's research has concentrated on NMDs, mainly on nemaline myopathy and previously also on myotubular myopathy. She initiated the ENMC International Consortium on Myotubular Myopathy in 1993 and coordinated its research activities until January 2000. The consortium organised altogether 9 workshops on nemaline myopathy (NM) and 7 on myotubular myopathy. Carina Wallgren-Pettersson initiated the informal network

called the Finnish Neuromuscular Club and was one of the initiators of the Finnish network on muscle disorders in children and, most recently, the European Reference Network NMD-FIN Consortium, now accepted as part of EURO-NMD.